LATEST

DEA slashes opioid drug productionThe US Drug Enforcement Administration (DEA) has reduced the amount of almost every Schedule II opiate and opioid medication that may be manufactured in the US by 25% or more.
Drug maker pays out millions over EpiPen chargesAs Mylan continues to face criticism over price hikes on its EpiPen epinephrine injection, the company agreed to a $465 million settlement with the U.S. Department of Justice and other agencies for overcharging on the EpiPen.
First "artificial pancreas" for diabetes approved, plus 2 more FDA actionsFDA recently approved several medications and devices across several therapy areas: diabetes, weight loss and rare, auto-inflammatory diseases. Here are the top 3 new approvals.
Aggressive blood sugar control slows diabetic eye disease progressionNIH-funded study shows less diabetic retinopathy progression among those who underwent intensive glycemic control.
Know these barriers to reduce type 2 diabetes costsIMS Health study: Up to 15% of healthcare system costs avoidable and effective patient activation by multiple stakeholders is key to driving improvement.
Invokamet extended-release approved for diabetesFDA recently approved an expanded use for Invokamet (Janssen): Invokamet XR, an extended-release combination drug to treat type 2 diabetes. The original Invokamet was approved by FDA in 2014.

Poll

View Results